News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

EKF diagnostic GmbH Exhibiting Cutting-Edge POC Technology at Hospitalar 2013



5/16/2013 1:16:20 PM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Cardiff, UK – 16th May 2013 – EKF Diagnostics, worldwide manufacturer of point-of-care (POC) diagnostic tools, will be exhibiting its innovative range of analysers for use in the detection and management of diabetes, anaemia, lactate and kidney related diseases at Hospitalar 2013, Sao Paulo, Brazil (21-24 May).

On display in Green Hall - L81 - Stand 14 will be the new Quo-Lab and Quo-Test glycated haemoglobin (HbA1c) analysers for near-patient measurement and monitoring of diabetes. HbA1c monitoring is increasingly used in the detection and management of diabetes and both analysers provide highly accurate, affordable and easy-to-use technology, which uses just 4 µL of venous or finger prick blood to deliver lab-accurate results within four minutes.

Small and lightweight, Quo-Lab is designed specifically to meet the needs of clinics and laboratories in emerging economies, where diabetes is an increasingly large public health issue, and is ideal for GP surgeries, diabetes clinics and laboratories.

Also on show will be EKF’s globally successful haemoglobin analyser, Hemo Control (also sold as HemoPoint H2 in USA and Asia). This portable and robust analyser delivers lab quality results within 25 seconds (CV of <2%) for both haemoglobin and haematocrit from one simple test and, new for 2013, includes pre-loaded data management software.

Hemo Control uses unique microcuvette technology – the NXT microcuvette. This enables precise and easy blood collection and significantly reduces the risk of air bubbles appearing in blood samples. By minimising occurrences of air bubbles in a sample, the NXT microcuvette ensures less waste with subsequent cost reductions.

Commenting on the production of the 33,333rd Hemo Control analyser, Julian Baines, Group CEO, EKF Diagnostics Holdings plc., said, “A decade on from its launch, Hemo Control is more popular than ever before, and sales of devices and microcuvettes continue to grow. Our success in winning large government orders in Mexico, Peru and Tanzania, as well as our increasing market share in the USA under the HemoPoint H2 brand, demonstrates the strength of the brand in a very competitive market.”

EKF’s Lactate Scout+ hand-held lactate analyser, that requires just 0.5ul of capillary blood and returns results in 10 seconds, will also be showcased. Lactate has traditionally been used in sports medicine to monitor athlete performance, however, EKF are now working with a number of new partners who are developing applications in obstetrics using the Lactate Scout+ analyser and strip sensor technology.

Throughout Hospitalar 2013, EKF experts will be available to offer practical advice about how EKF’s cutting-edge solutions are revolutionising the use of diagnostics in point-of-care settings and improving patient outcomes.

For more information, please visit www.ekfdiagnostics.com. This release can also be viewed online at: http://www.ekfdiagnostics.com/news.aspx?id=94.

About EKF Diagnostics

www.ekfdiagnostics.com

EKF Diagnostics Holdings plc specialises in the development, production and worldwide distribution of point-of-care blood analysers for use in the detection and management of diabetes, anaemia, lactate and kidney related diseases.

EKF Diagnostics’ expertise covers the entire in vitro diagnostics chain, from fermentation and enzyme production, to the manufacture of liquid reagents, the design and building of world-class diagnostic devices and the distribution of rapid test kits for infectious diseases and pregnancy. The EKF range of analysers are a trusted brand in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for the measurement of glucose, lactate, haemoglobin, haematocrit and HbA1c.

EKF Diagnostics products are sold in more than 100 countries around the globe. EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.

EKF Diagnostics acquired Texas-based Stanbio Laboratory in June 2011. Stanbio manufactures and sells clinical chemistry reagents as well as a range of rapid tests and analysers for point of care and laboratory use.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES